High-Sensitivity CRP: What This Inflammation Test Can Tell You About Heart Risk

CRP (C-reactive protein) is produced by the liver in response to inflammatory signals throughout the body. Standard CRP assays were originally designed to detect the much higher concentrations seen in acute inflammation and infection. High-sensitivity assays were developed specifically to detect the lower concentrations relevant to the chronic, low-grade inflammation associated with atherosclerosis — a different clinical use case from standard CRP testing for suspected infection.

hs-CRP is most useful in a specific clinical scenario: someone whose calculated 10-year cardiovascular risk sits in an intermediate range where the decision to start or intensify preventive therapy is genuinely uncertain. In that situation, an elevated hs-CRP can shift the risk estimate upward and support a more proactive approach; a low hs-CRP can support a more conservative one. Outside of that intermediate-risk, decision-uncertain scenario, hs-CRP adds comparatively little to risk assessment already established by other factors.

The CDC/AHA 2003 workshop established the widely used cardiovascular risk tertiles — low risk under 1 mg/L, average risk 1 to 3 mg/L, and high risk above 3 mg/L — based on population distribution data. The 2018 AHA/ACC cholesterol guideline separately references an hs-CRP of 2.0 mg/L or higher as a "risk-enhancing factor" that can favor starting statin therapy when a treatment decision is otherwise uncertain. It’s important to distinguish these cardiovascular-risk-relevant concentrations (generally under 10 mg/L) from the much higher concentrations — 10 to 40 mg/L and above — associated with acute inflammation and infection; these represent fundamentally different clinical contexts, not points on the same risk scale.

Almost any acute inflammatory process can raise hs-CRP: a common cold, a minor injury, recent dental work, a urinary tract infection, or a flare of a chronic inflammatory condition like rheumatoid arthritis or inflammatory bowel disease. Because of this sensitivity, current guidance generally recommends against interpreting a single hs-CRP drawn during acute illness as reflective of stable cardiovascular risk, and a repeat measurement under calmer conditions is the standard approach when an unexpectedly high result appears.

hs-CRP does not diagnose blocked or narrowed arteries, does not confirm the presence of atherosclerosis, and does not identify a specific cardiovascular event risk timeline. It also cannot distinguish cardiovascular-related inflammation from inflammation caused by an unrelated condition — the number itself carries no information about its source.

A common misunderstanding is treating an elevated hs-CRP as evidence of heart disease itself, when it’s a nonspecific inflammatory marker that requires the broader clinical context — including whether it was drawn during illness — to interpret meaningfully. Another misunderstanding is using hs-CRP to track whether a treatment is "working," which current guidance specifically advises against; hs-CRP is not established as a monitoring tool for treatment response.

If your hs-CRP comes back elevated and you were sick, injured, or dealing with a flare of a chronic condition around the time of testing, a repeat test once you’re feeling well is a reasonable next step before drawing any cardiovascular conclusions. If your cardiovascular risk is otherwise intermediate and uncertain, discussing how an hs-CRP result fits into that broader risk conversation with a clinician is more useful than interpreting the number alone.

hs-CRP’s nonspecific nature means it consistently requires clinical context — recent illness, injury, or chronic inflammatory conditions — to interpret meaningfully, and it is not established as a tool for monitoring treatment response over time.

Read alongside the Elements84 lipid panel guide, the LDL guide, and the Lipoprotein(a) guide, since hs-CRP is used to refine — not replace — risk assessment built on these measures.